Abzena

Abzena is the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules with headquarters in San Diego, CA and additional centres of excellence in Bristol, PA and Cambridge, UK. Abzena has extensive experience in developing Biologics and Bioconjugates, and provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. Forward-thinking and committed, Abzena finds the best solutions and uses the right technologies to design, develop and manufacture products to ensure we get vital medicines to patients. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors and Biospring Partners.